Clinical Trials Browser

Phase 1 × OTHER × Spinal Puncture × Clear all

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

Burkitt Lymphoma

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06871410 2026-01-26

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03025256 2026-01-08

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase 1 Active not recruiting

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT05359211 2025-09-15

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06896110 2025-06-26

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Phase 1 Enrolling by invitation

Astrocytoma, Glioblastoma